Published 3 days ago • loading... • Updated 3 days ago

Espervita's EVT0185 Demonstrates Reversal of Metabolic Dysfunction and Liver Fibrosis in Cell Metabolism Publication

On Jan. 6, 2026 in Ann Arbor, Mich., Espervita Therapeutics announced a Cell Metabolism publication showing EVT0185, a first-in-class dual ACLY/ACSS2 inhibitor, resolves MASH and liver fibrosis while lowering blood glucose and cholesterol.
Obesity and type 2 diabetes affect hundreds of millions and drive MASH, now the fastest-growing cause of advanced liver disease, liver cancer and transplantation, creating an unmet need for fibrosis-reversing therapies.
Preclinical studies demonstrated 38% reversal of hepatic fibrosis with direct inhibition of HSCs, alongside improved insulin sensitivity and reduced steatosis and inflammation without increased plasma triglycerides.
Together, preclinical and prior tumor data imply efficacy in human liver slices and primary human HSCs supports clinical translatability, with potential to address downstream complications.
Mechanistically, EVT0185 reprograms cytosolic acetyl-CoA metabolism in HSCs and hepatocytes by inhibiting ACLY and ACSS2, targeting metabolic drivers of fibrosis and systemic dysfunction.

Insights by Ground AI

14 Articles

abc12/WJRT

+13 Reposted by 13 other sources

Center

Espervita's EVT0185 Demonstrates Reversal of Metabolic Dysfunction and Liver Fibrosis in Cell Metabolism Publication

ANN ARBOR, Mich., Jan. 6, 2026 /PRNewswire/ -- Espervita Therapeutics, a biotechnology company developing targeted metabolic reprogramming therapies, announced the publication in Cell Metabolism of groundbreaking preclinical data demonstrating that its lead compound, EVT0185, a first-in-class dual inhibitor of ATP…

3 days ago·Flint, United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year